157 related articles for article (PubMed ID: 30685793)
21. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience.
Loteta B; Paviglianiti A; Naso V; Ferreri A; Moscato T; Console G; Canale FA; Irrera G; Pugliese M; Di Costanzo A; Provenzano PF; Loddo V; Porto G; Cusumano G; Russo L; Meliambro N; Romeo V; Porcino D; Gallo S; Gangemi T; Rossetti AM; Martino M
Support Care Cancer; 2022 Jan; 30(1):585-591. PubMed ID: 34347181
[TBL] [Abstract][Full Text] [Related]
22. Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA).
Lorusso V; Russo A; Giotta F; Codega P
Core Evid; 2020; 15():21-29. PubMed ID: 32802009
[TBL] [Abstract][Full Text] [Related]
23. Capsule-related dysphagia and the use of netupitant/palonosetron (Akynzeo™) capsules - A report of two cases and a solution.
Behbahany K; Bubalo J
J Oncol Pharm Pract; 2021 Jul; 27(5):1284-1286. PubMed ID: 33100182
[TBL] [Abstract][Full Text] [Related]
24. Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy.
Nelson WW; Vaidya V; Scott JA; Wang B; Lambert H; Holmes B; Bailey WL
Future Oncol; 2023 Jan; 19(1):29-36. PubMed ID: 36622264
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective.
Nilsson J; Piovesana V; Turini M; Lezzi C; Eriksson J; Aapro M
Support Care Cancer; 2022 Nov; 30(11):9307-9315. PubMed ID: 36074186
[TBL] [Abstract][Full Text] [Related]
26. Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Zelek L; Navari R; Aapro M; Scotté F
Cancer Med; 2023 Aug; 12(15):15769-15776. PubMed ID: 37537943
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation.
Bubalo JS; Radke JL; Bensch KG; Chen AI; Misra S; Maziarz RT
J Oncol Pharm Pract; 2024 Mar; 30(2):304-312. PubMed ID: 37151021
[No Abstract] [Full Text] [Related]
28. Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data.
Giuliani J; Bonetti A
Curr Opin Oncol; 2020 Jul; 32(4):269-273. PubMed ID: 32541312
[TBL] [Abstract][Full Text] [Related]
29. Retrospective Evaluation of a Dexamethasone Sparing Antiemetic Regimen: An Antiemetic Prophylaxis Study on NEPA (Netupitant Plus Palonosetron) for Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients.
Agre S; Agre M; Pol P; Tonse M; Mohanty M; Shaikh A
Cureus; 2023 Nov; 15(11):e49763. PubMed ID: 38161895
[TBL] [Abstract][Full Text] [Related]
30. Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.
Celio L; Cortinovis D; Cogoni AA; Cavanna L; Martelli O; Carnio S; Collovà E; Bertolini F; Petrelli F; Cassano A; Chiari R; Zanelli F; Pisconti S; Vittimberga I; Letizia A; Misino A; Gernone A; Bonizzoni E; Pilotto S; De Placido S; Bria E
BMC Cancer; 2022 Aug; 22(1):915. PubMed ID: 35999527
[TBL] [Abstract][Full Text] [Related]
31. Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy.
Navari RM; Nelson WW; Shoaib S; Singh R; Zhang W; Bailey WL
Adv Ther; 2023 Jul; 40(7):3217-3226. PubMed ID: 37245189
[TBL] [Abstract][Full Text] [Related]
32. Netupitant PET imaging and ADME studies in humans.
Spinelli T; Calcagnile S; Giuliano C; Rossi G; Lanzarotti C; Mair S; Stevens L; Nisbet I
J Clin Pharmacol; 2014 Jan; 54(1):97-108. PubMed ID: 24122871
[TBL] [Abstract][Full Text] [Related]
33. Phase 3 Study of Palonosetron IV Infusion Vs. IV Bolus for Chemotherapy-Induced Nausea and Vomiting Prophylaxis After Highly Emetogenic Chemotherapy.
Karthaus M; Voisin D; Rizzi G; Ciuleanu T
J Pain Symptom Manage; 2020 Sep; 60(3):568-576. PubMed ID: 32276098
[TBL] [Abstract][Full Text] [Related]
34. A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.
Hesketh PJ; Aapro M; Jordan K; Schwartzberg L; Bosnjak S; Rugo H
Biomed Res Int; 2015; 2015():651879. PubMed ID: 26421300
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of contemporary olanzapine- and netupitant/palonosetron-containing antiemetic regimens for chemotherapy-induced nausea and vomiting.
Yip CC; Li L; Lau TKH; Chan VTC; Kwok CCH; Suen JJS; Mo FKF; Yeo W
Hong Kong Med J; 2023 Feb; 29(1):49-56. PubMed ID: 36810240
[TBL] [Abstract][Full Text] [Related]
36. Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.
Celio L; Cortinovis D; Cogoni AA; Cavanna L; Martelli O; Carnio S; Collovà E; Bertolini F; Petrelli F; Cassano A; Chiari R; Zanelli F; Pisconti S; Vittimberga I; Letizia A; Misino A; Gernone A; Bonizzoni E; Pilotto S; De Placido S; Bria E
Oncologist; 2021 Oct; 26(10):e1854-e1861. PubMed ID: 34101934
[TBL] [Abstract][Full Text] [Related]
37. Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant.
Tyler T; Schultz A; Venturini A; Giuliano C; Bernareggi A; Spezia R; Voisin D; Stella V
Clin Pharmacol Drug Dev; 2022 Dec; 11(12):1405-1418. PubMed ID: 36263927
[TBL] [Abstract][Full Text] [Related]
38. Oral versus intravenous palonosetron in Chinese cancer patients receiving moderately emetogenic chemotherapy: A non-inferiority phase III trial.
Cui J; Zhang Q; Zhang H; Spinelli T; Nicolas P; Li W
Eur J Cancer Care (Engl); 2020 Jul; 29(4):e13245. PubMed ID: 32567124
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India.
Vaswani B; Bhagat S; Patil S; Barkate H
World J Clin Oncol; 2020 Aug; 11(8):606-613. PubMed ID: 32879847
[TBL] [Abstract][Full Text] [Related]
40. Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation.
Apolito V; Giaccone L; Ferrero S; Larocca A; Cavallo F; Coscia M; Beggiato E; Butera S; Martella F; Dainese C; Cetani G; Scaldaferri M; Cattel F; Boccadoro M; Ferrero D; Bruno B; Cerrano M
Ann Hematol; 2020 Sep; 99(9):2197-2199. PubMed ID: 32661577
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
